• Bonti Announces Results of Phase 2a Scar Reduction Clinical Study

    4 monthes ago - By Surgical Aesthetics Magazine

    Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company's EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E with a unique clinical profile, characterized by a faster onset of action and a shorter duration of activity compared to botulinum neurotoxin serotype A products.
    For the randomized, placebo-controlled, double-blind trial, EB-001A or placebo was...
    Read more ...